Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Saturday. The firm issued a hold rating on the medical research company’s stock.

CTSO has been the subject of several other reports. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $1.15 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The firm has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $1.04. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The company has a market capitalization of $62.88 million, a P/E ratio of -3.19 and a beta of 0.61.

Hedge Funds Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently bought and sold shares of CTSO. Millennium Management LLC acquired a new position in Cytosorbents during the fourth quarter worth approximately $30,000. Renaissance Technologies LLC increased its position in Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the last quarter. Northern Trust Corp increased its position in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Cytosorbents during the fourth quarter worth approximately $99,000. Finally, Geode Capital Management LLC grew its stake in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.